ArticleScientific reports2025
Co-administration of low-dose-Naltrexone and Carbamazepine remarkedly ameliorate allodynia and cognitive deficit in a rat model of trigeminal neuralgia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vorinostat Rescues Cognitive Deficits in a Neuroinflammatory Mouse Model: A Study of Sex Differences and the Underlying TLR4/NF-κB Mechanism.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to examine the pain-relieving effects of combining Carbamazepine (CBZ) and low-dose-Naltrexone (LDN) in trigeminal neuralgia (TN) to reduce the side effects of CBZ and the potential of synergistic antiallodynic interaction. Male Wistar rats were allocated randomly to 8 groups: Control, Sham, TN, TN (CBZ 100 mg), TN (CBZ 100 mg oral (p.o.) + LDN 0.5 mg, intraperitoneal (i.p.)), TN (CBZ 30 mg + LDN 0.5 mg), TN (CBZ 10 mg + LDN 0.5 mg), and TN (LDN 0.5 mg). TN was induced through chronic constriction injury of the infraorbital nerve (CCI-ION) . To evaluate hyperalgesia, we employed the von Frey, acetone, and air puff tests. Cognitive functions were assessed using the open field, elevated plus maze, tail suspension, and passive avoidance tests. Furthermore, total antioxidant capacity levels (TAC) were measured in the spinal trigeminal nucleus. Administering oral CBZ (100 mg) along with LDN for 7 days significantly reduced CCI-ION-induced mechanical allodynia and improved anxiety, depression, and passive avoidance learning and memory compared to the TN group. Co-administration of LDN and CBZ more effectively alleviated anxiety and depression than CBZ alone. The TN (LDN) group demonstrated significantly better avoidance memory compared to the TN (CBZ100) group. The TN group exhibited a lower TAC level compared to the sham group, and TAC levels were improved in the TN (CBZ 100 + LDN) and TN (LDN) groups. The data indicate that combining CBZ with LDN effectively reduces mechanical allodynia in TN rats, while LDN may also improve anxiety, depression, and cognitive impairment caused by chronic TN pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.